PBRM1改变作为肾细胞癌免疫检查点抑制剂反应标志物的临床验证
Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma.
作者信息
Braun David A, Ishii Yuko, Walsh Alice M, Van Allen Eliezer M, Wu Catherine J, Shukla Sachet A, Choueiri Toni K
机构信息
Dana-Farber Cancer Institute, Boston, Massachusetts.
Bristol-Myers Squibb, Lawrenceville, New Jersey.
出版信息
JAMA Oncol. 2019 Nov 1;5(11):1631-1633. doi: 10.1001/jamaoncol.2019.3158.
Abstract
This cohort study examines whether alterations are associated with response to immune checkpoint inhibitor treatment in patients with metastatic clear cell renal cell carcinoma.
摘要
这项队列研究旨在探讨转移性透明细胞肾细胞癌患者的改变是否与免疫检查点抑制剂治疗反应相关。
相似文献
1
Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma.
JAMA Oncol. 2019 Nov 1;5(11):1631-1633. doi: 10.1001/jamaoncol.2019.3158.
2
The Impact of PBRM1 Expression as a Prognostic and Predictive Marker in Metastatic Renal Cell Carcinoma.
J Urol. 2015 Oct;194(4):1112-9. doi: 10.1016/j.juro.2015.04.114. Epub 2015 May 18.
3
Commentary on "Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation." Kapur P, Peña-Llopis S, Christie A, Zhrebker L, Pavía-Jiménez A, Rathmell WK, Xie XJ, Brugarolas J. Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX. Lancet Oncol 2013; 14(2):159-67. [Epub 2013 Jan 16]. doi: 10.1016/S1470-2045(12)70584-3.
Urol Oncol. 2014 Aug;32(6):934-5. doi: 10.1016/j.urolonc.2014.01.012.
4
Polybromo-1 (PBRM1), a SWI/SNF complex subunit is a prognostic marker in clear cell renal cell carcinoma.
BJU Int. 2014 May;113(5b):E157-63. doi: 10.1111/bju.12426. Epub 2013 Dec 2.
5
Prognostic and Predictive Value of in Clear Cell Renal Cell Carcinoma.
Cancers (Basel). 2019 Dec 19;12(1):16. doi: 10.3390/cancers12010016.
6
PBRM1 bromodomains variably influence nucleosome interactions and cellular function.
J Biol Chem. 2018 Aug 31;293(35):13592-13603. doi: 10.1074/jbc.RA118.003381. Epub 2018 Jul 9.
7
Radiogenomics in Clear Cell Renal Cell Carcinoma: Machine Learning-Based High-Dimensional Quantitative CT Texture Analysis in Predicting PBRM1 Mutation Status.
AJR Am J Roentgenol. 2019 Mar;212(3):W55-W63. doi: 10.2214/AJR.18.20443. Epub 2019 Jan 2.
8
Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
Lancet Oncol. 2018 Dec;19(12):1688-1698. doi: 10.1016/S1470-2045(18)30648-X. Epub 2018 Nov 8.
9
Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression.
J Urol. 2016 Jan;195(1):180-7. doi: 10.1016/j.juro.2015.07.113. Epub 2015 Aug 20.
10
Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
Neoplasia. 2019 Feb;21(2):247-256. doi: 10.1016/j.neo.2018.12.006. Epub 2019 Jan 16.
引用本文的文献
1
BAP1 as a predictive biomarker of therapeutic response to oncolytic vaccinia virus for metastatic renal cell carcinoma therapy.
Cancer Immunol Immunother. 2025 Aug 6;74(9):282. doi: 10.1007/s00262-025-04139-4.
2
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial.
Nat Med. 2025 Aug 1. doi: 10.1038/s41591-025-03867-5.
3
Second-Line Systemic Therapies in Metastatic Renal Cell Carcinoma: Current Insights and Future Directions.
J Cancer Immunol (Wilmington). 2025;7(2):81-94. doi: 10.33696/cancerimmunol.7.107.
4
Precision Oncology in Rare Endocrine and Neuroendocrine Neoplasms: Experiences and Challenges of the CCCMunich Molecular Tumor Board.
Target Oncol. 2025 Jun 30. doi: 10.1007/s11523-025-01152-6.
5
Molecular Genetics of Renal Cell Carcinoma: A Narrative Review Focused on Clinical Relevance.
Curr Oncol. 2025 Jun 18;32(6):359. doi: 10.3390/curroncol32060359.
6
Characterisation of an autochthonous mouse ccRCC model of immune checkpoint inhibitor therapy resistance.
Sci Rep. 2025 Jun 5;15(1):19818. doi: 10.1038/s41598-025-04917-1.
7
Prognostic impact and landscape of cellular CXCR5 chemokine receptor expression in clear-cell renal cell carcinoma.
Cancer Immunol Immunother. 2025 Apr 10;74(5):166. doi: 10.1007/s00262-025-04020-4.
8
Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma.
Nat Cancer. 2025 Feb;6(2):372-384. doi: 10.1038/s43018-024-00896-w. Epub 2025 Jan 9.
9
The role of tumor types in immune-related adverse events.
Clin Transl Oncol. 2024 Dec 30. doi: 10.1007/s12094-024-03798-6.
10
Exploring the Prognostic Value of Tumour-Associated Genes in Clear Cell Renal Cell Carcinoma Through Single-Cell RNA Sequencing Insights.
J Cell Mol Med. 2024 Dec;28(24):e70297. doi: 10.1111/jcmm.70297.
Zotero 插件